NASDAQ:CDNA
CareDx Stock News
$7.76
-0.440 (-5.37%)
At Close: Apr 30, 2024
CareDx to Host Symposium at CEoT Featuring the Latest Multimodality Innovations in Kidney and Lung Transplant Surveillance
11:00am, Wednesday, 06'th Apr 2022 GlobeNewswire Inc.
Symposium, “Improved Precision with a Multimodality Approach,” Reviews Innovative Solutions for a More Holistic View of Allograft Health Symposium, “Improved Precision with a Multimodality Appro
CareDx Partners with the European Society for Organ Transplantation to Provide Clinical Evidence Supporting the Use of AlloSeq cfDNA with European Transplant Healthcare Professionals
11:00am, Wednesday, 30'th Mar 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically d
CareDx’s AlloCare App Now Integrated with TxAccess to Help Pre-Transplant Patients Navigate the Waitlist Process
11:00am, Thursday, 24'th Mar 2022 GlobeNewswire Inc.
New Features Aim to Help More Patients with Kidney Failure Receive an Organ Transplant New Features Aim to Help More Patients with Kidney Failure Receive an Organ Transplant
UPDATE -- CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community
10:00am, Wednesday, 23'rd Mar 2022 GlobeNewswire Inc.
Jury Finds Natera Falsely Advertised its Prospera Kidney Transplant Technology Jury Finds Natera Falsely Advertised its Prospera Kidney Transplant Technology
Miromatrix to Participate in CareDx''s Xenotransplantation Innovation Day
08:01pm, Wednesday, 16'th Mar 2022 Benzinga
EDEN PRAIRIE, Minn., March 16, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO ), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients'' lives, announced its participation in CareDx''s Xenotransplantation Innovation Day, a virtual event that will feature a leading panel of transplant experts who will share the latest advancements in the field. CareDx''s Xenotransplantation Innovation Day will be held on March 22, 2022, from 11:00 am to 12:00 pm Central Time / 12:00 pm to 1:00 pm Eastern Time. The presentations and panel discussions will be held in a virtual format to enable a wide audience to learn from these experts. The symposium will include an update on the world''s first living pig-to-human heart transplant from the University of Maryland School of Medicine, an update on the world''s first transplant of a gene-edited pig kidney from NYU Langone Health, and a development update regarding human-compatible organs from eGenesis and an update on bioengineered livers and kidneys for transplant from Miromatrix.
Transplant Advocates Say Federal Jury''s False Advertising Verdict Benefits Patients Whose Lives Rely Upon Rigorous, Reliable Science
11:00am, Wednesday, 16'th Mar 2022 Benzinga
LITHIA, Fla., March 16, 2022 (GLOBE NEWSWIRE) -- The nonprofit Transplant Recipients International Organization (TRIO) today praised a federal jury''s $44.9 million verdict award to CareDx, Inc., finding that a transplant test provider and its senior executives intentionally and recklessly made misleading statements about the veracity of its test for kidney transplant effectiveness. "The verdict handed down on Monday ultimately benefits patients whose lives depend on rigorous, reliable science and clinical excellence," said TRIO President James … Full story available on Benzinga.com
CareDx wins $45 mln verdict against Natera for false advertising
06:37pm, Tuesday, 15'th Mar 2022 Reuters
Genetic testing company Natera Inc owes rival CareDx Inc $44.9 million for making false claims about the effectiveness of Natera''s Prospera test for assessing the risk that a person''s body will reject a kidney transplant, a Delaware jury said.
CareDx wins $44.9M in false advertising trial against Natera (NASDAQ:CDNA)
06:31am, Tuesday, 15'th Mar 2022 Seeking Alpha
CareDx (CDNA) announced that the Company won its false advertising case against Natera (NTRA) as a jury found that Natera and its senior executives intentionally and recklessly misled…
CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community
12:06am, Tuesday, 15'th Mar 2022 GlobeNewswire Inc.
Jury Finds Natera Falsely Advertised its Prospera Kidney Transplant Technology Jury Finds CareDx Advertising of AlloSure to be Accurate and Truthful Jury Finds Natera Falsely Advertised its Prospera K
Bragar Eagel & Squire, P.C. Is Investigating Agrify, Cronos, Everbridge, and CareDx and Encourages Investors to Contact the Firm
02:00am, Thursday, 10'th Mar 2022 GlobeNewswire
NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agrify Corporation (NASDAQ: AGFY), Cronos Group, Inc. (NASDAQ: CRON), Everbridge, Inc. (NASDAQ: EVBG), and CareDx, Inc. (NASDAQ: CDNA). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
CareDx''s partner Cibiltech begins trial of iBox AI to monitor kidney transplant patients
01:56pm, Thursday, 03'rd Mar 2022 Seeking Alpha
CareDx (CDNA) said its French strategic partner Cibiltech began the CIBIL clinical trial to evaluate the performance of iBox artificial intelligence ((AI)) as a prognostic measure of…
CareDx, Inc (CDNA) CEO Reg Seeto on Q4 2021 Results - Earnings Call Transcript
01:46am, Friday, 25'th Feb 2022 Seeking AlphaCareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates
10:50pm, Thursday, 24'th Feb 2022 Zacks Investment Research
CareDx (CDNA) delivered earnings and revenue surprises of -250% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CareDx Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $79.22M beats by $1.12M (NASDAQ:CDNA)
09:24pm, Thursday, 24'th Feb 2022 Seeking Alpha
CareDx press release (NASDAQ:CDNA): Q4 Non-GAAP EPS of -$0.03 misses by $0.06.Revenue of $79.22M (+35.1% Y/Y) beats by $1.12M.
CareDx Reports Fourth Quarter and Full Year 2021 Results
09:01pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically di